calendar
2,152 catalysts · 18,987 approval · 5,000 device 510k · 4,728 grant · 3,921 phase readout · 2,141 8k filing · 2,000 device pma
next 91 dayslessmore
MonWedFri
2,152 catalysts · 18,987 approval · 5,000 device 510k · 4,728 grant · 3,921 phase readout · 2,141 8k filing · 2,000 device pma
Items: 7.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 1.01, 8.01, 9.01
Items: 7.01, 8.01, 9.01
Items: 5.02, 9.01
Items: 5.02, 9.01
Items: 1.02
Items: 8.01
Items: 8.01
Items: 2.02, 7.01, 9.01
Items: 5.02
Items: 5.02, 5.07, 9.01
Items: 7.01, 8.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 2.02, 9.01
Items: 8.01
Items: 7.01, 9.01
Items: 1.01, 7.01, 8.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 7.01, 9.01
Items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections
Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S
Items: 1.01, 7.01, 9.01
Items: 1.01, 9.01
Items: 3.01
Items: 5.02
Items: 8.01, 9.01
Items: 5.02, 9.01
Items: 1.01, 2.03, 9.01
Items: 5.02, 9.01
Items: 1.01, 3.01, 9.01
Items: 8.01, 9.01
Items: 5.02
Items: 5.02, 9.01
Items: 1.01, 8.01, 9.01
Items: 5.02
Items: 5.02
Items: 1.01, 2.01, 3.02, 9.01
Items: 9.01
Items: 5.07
Items: 1.01, 8.01, 9.01
Items: 1.01, 3.02, 9.01
Items: 1.01, 9.01
Items: 5.03, 9.01
Items: 1.01, 9.01
Items: 5.02, 9.01
Items: 2.03
Items: 7.01, 8.01, 9.01
Items: 2.04